



SIDLEY AUSTIN LLP
1501 K STREET, N.W.
WASHINGTON, D.C. 20005
TEL. +1 202 736 8000
FAX +1 202 736 8711

RECEIVED
CENTRAL FAX CENTER

JAN 11 2006

FAX TRANSMISSION

Total 4 pages, including cover sheet

To: Commissioner for Patents
U.S. Patent and Trademark Office Fax no.: (571) 273-8300
From: David L. Fitzgerald, Reg. no. 47,347
Tel. (202) 736-8818
Date: 11 January 2006


Re:

Serial No.:	09/911,692	Group Art Unit:	1644
Confirmation No.:	8484	Examiner:	R. Schwadron
Filed:	25 July 2001	Atty. Docket No.:	27693-01009
Applicant:	Darrell R. ANDERSON et al.		
For:	Expression and Use of Anti-CD20 Antibodies		


CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

I CERTIFY THAT THE FOLLOWING DOCUMENTS ARE BEING TRANSMITTED TO THE USPTO AT FAX NUMBER (571) 273-8300 ON THE DATE SHOWN:

- Transmittal (1 page) and Power of Attorney by Assignee (2 pages)


SIGNATURE


PRINTED NAME


DATE

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE US POSTAL SERVICE. THANK YOU.

Serial no. 09/911,692

Attorney Docket no. 27693-01009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

Serial No.:	09/911,692	Group Art Unit:	1644
Confirmation No.:	8484	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Expression and Use of Anti-CD20 Antibodies		

JAN 11 2006

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL FOR POWER OF ATTORNEY

Transmitted for filing in the captioned application is a combined Power of Attorney by the assignee and Change of Correspondence Address. We believe that no fee is due in connection with this submission.

Should any fee under 37 C.F.R. §§ 1.16 or 1.17 be required to render this or any other paper filed during the pendency of this application timely or proper, the Director is requested to charge the appropriate amount to our Deposit Account No. 18-1260.

Respectfully submitted,



David L. Fitzgerald, Reg. No. 47,347
 Attorney for Biogen Idec Inc.

Date: 11 January 2006

SIDLEY AUSTIN LLP
 1501 K Street, N.W.
 Washington, DC 20005
 tel. (202) 736-8818
 fax (202) 736-8711

SI 0029 CP1C3

Serial no. 09/911,692

Attorney Docket no. 27693-01009

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 11 2006

Serial No.:	09/911,692	Group Art Unit:	1644
Confirmation No.:	8484	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Expression and Use of Anti-CD20 Antibodies		

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS

The assignee of the entire right, title, and interest in U.S. patent application serial no. 09/911,692, Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified application and appoints the practitioners associated with

CUSTOMER NUMBER 47553

as its attorneys and agents to prosecute the captioned patent application, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct all correspondence regarding this application to the address associated with **CUSTOMER NUMBER 47553**.

Please note the new attorney docket number for this application, 27693-01009.

This application is a continuation of application serial no. 08/475,813, filed 07 June 1995, now U.S. Patent No. 6,682,734; which is a divisional of application serial no. 08/149,099, now U.S. Patent No. 5,736,137. Assignments of the '137 patent have effect as to this application. M.P.E.P. § 306.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned application by virtue of the following assignments for U.S. Patent No. 5,736,137 recorded in the Patent and Trademark Office:

BI 0029 CP1C3

Serial no. 09/911,692

Attorney Docket no. 27693-01009

From the inventors to IDEC Pharmaceuticals Corp.,	recorded at Reel 006850, Frame 0468;
From IDEC Pharmaceuticals Corp. to Merrill Lynch/Morgan Stanley Associates, L.P.,	Reel 007171, Frame 0587;
From Merrill Lynch/Morgan Stanley Associates, L.P. to IDEC Pharmaceuticals Corp.,	Reel 007934, Frame 0284.

The following documents regarding the '137 patent are also recorded in the Office:


From IDEC Pharmaceuticals Corp. in favor of Silicon Valley Bank as collateral agent for Venture Lending & Leasing, Inc., granting a security interest,	recorded at Reel 007279, Frame 0680;
From Venture Lending & Leasing, Inc. in favor of IDEC Pharmaceuticals Corp., releasing all security interests,	Reel 010340, Frame 0869.

Biogen Idec Inc. is the successor in interest to IDEC Pharmaceuticals Corp.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,


Christopher A. Dayton
Associate General Counsel, IP
Biogen Idec Inc.


Date